Sales for this month
August 2026Fiscal year ending March 2027The key figures that our group has set as management targets are disclosed monthly.
Disclosed around the middle of each month or later. The June, September, December and March figures are disclosed on the same day as the announcement of quarterly financial results.
Month April 2025 / Net Premiums Written 5,134, Month May 2025 / Net Premiums Written 5,424, Month June 2025 / Net Premiums Written 5,220, Month July 2025 / Net Premiums Written 5,175, Month August 2025 / Net Premiums Written 5,332
Scope of aggregation: The Group (pet insurance business and synergy creation business)
| Item | Details |
|---|---|
| Month Covered | August 2026 |
| Fiscal Year Covered | Fiscal year ending March 2027 |
| Scope of aggregation | The Group (pet insurance business and synergy creation business) |
| Net sales for the month | ¥5,674 million (net premiums written) |
| Year-on-year change in monthly net sales | 106.4 |
| Key KPIs | Indicator name Number of in-force policies / Value 1,426,015 Engagements / Year on year 106.6 Engagements, Indicator name Average renewal rate / Value 88.7 ％ / Year on year 100.3 ％, Indicator name Doubutsu Kenkatsu program (gut flora testing) applications / Value 23,523 Engagements / Year on year 105.7 Engagements, Indicator name Patents held / Value 31 Engagements / Year on year 124 Engagements, Indicator name JARVIS Tokyo revenue / Value ¥76,691 thousand / Year on year not_calculable (the same month of the previous year was "-") |
| Monthly Commentary | The key figures that our group has set as management targets are disclosed monthly. |
| Monthly trend for the same period last year | Month April 2025 / Net Premiums Written 5,134, Month May 2025 / Net Premiums Written 5,424, Month June 2025 / Net Premiums Written 5,220, Month July 2025 / Net Premiums Written 5,175, Month August 2025 / Net Premiums Written 5,332 |
| Next Scheduled Disclosure | Disclosed around the middle of each month or later. The June, September, December and March figures are disclosed on the same day as the announcement of quarterly financial results. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company has not explained the reasons for changes in individual metrics. The number of patents held is disclosed as a key figure related to the promotion of Bio Insurtech toward becoming a preventive insurance company. JARVIS Tokyo revenue is disclosed as a metric related to the advanced veterinary medical facility that opened in October 2025.